These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25765788)

  • 1. [The C5 gene polymorphism in patients with PNH].
    Nishimura J; Kanakura Y
    Rinsho Ketsueki; 2015 Feb; 56(2):103-10. PubMed ID: 25765788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic variants in C5 and poor response to eculizumab].
    Nishimura J
    Rinsho Ketsueki; 2015 Jul; 56(7):855-60. PubMed ID: 26251149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in C5 and poor response to eculizumab.
    Nishimura J; Yamamoto M; Hayashi S; Ohyashiki K; Ando K; Brodsky AL; Noji H; Kitamura K; Eto T; Takahashi T; Masuko M; Matsumoto T; Wano Y; Shichishima T; Shibayama H; Hase M; Li L; Johnson K; Lazarowski A; Tamburini P; Inazawa J; Kinoshita T; Kanakura Y
    N Engl J Med; 2014 Feb; 370(7):632-9. PubMed ID: 24521109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
    Merrill SA; Brodsky RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria.
    Luzzatto L; Gianfaldoni G
    Int J Hematol; 2006 Aug; 84(2):104-12. PubMed ID: 16926130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular genetics, biochemistry, and biology of PNH].
    Kinoshita T
    Rinsho Ketsueki; 2017; 58(4):353-362. PubMed ID: 28484166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
    Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
    Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
    Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR
    J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
    Richards SJ; Hill A; Hillmen P
    Cytometry B Clin Cytom; 2007 Sep; 72(5):291-8. PubMed ID: 17549742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases.
    Fukuzawa T; Nezu J
    Curr Med Chem; 2020; 27(25):4157-4164. PubMed ID: 31622197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical progress of paroxysmal nocturnal hemoglobinuria].
    Gong YW; He GS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1627-30. PubMed ID: 24370061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful management of orthopedic operations requiring general anesthesia in a PNH patient after introduction of eculizumab].
    Tsutsui M; Gotoh A; Yasuda H; Ono E; Tanaka M; Komatsu N
    Rinsho Ketsueki; 2015 Apr; 56(4):423-7. PubMed ID: 25971274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
    Loschi M; Porcher R; Barraco F; Terriou L; Mohty M; de Guibert S; Mahe B; Lemal R; Dumas PY; Etienne G; Jardin F; Royer B; Bordessoule D; Rohrlich PS; Fornecker LM; Salanoubat C; Maury S; Cahn JY; Vincent L; Sene T; Rigaudeau S; Nguyen S; Lepretre AC; Mary JY; Corront B; Socie G; Peffault de Latour R
    Am J Hematol; 2016 Jun; 91(4):366-70. PubMed ID: 26689746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.
    Alashkar F; Weber SN; Vance C; Herich-Terhürne D; Dührsen U; Lammert F; Röth A
    Eur J Haematol; 2017 Oct; 99(4):350-356. PubMed ID: 28692147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria.
    Du Y; Zhang Q; Han B
    Int J Lab Hematol; 2016 Aug; 38(4):e84-5. PubMed ID: 27307199
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.